A quick peek into the report
Table of Contents
1.1 Inclusion and Exclusion
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
2.3 Global Genomic Data Analysis and Interpretation Market: Research Methodology
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4.1 Market Definition
4.2 Market Footprint and Growth Potential, $Million, 2019-2030
4.3 COVID-19 Impact on Global Genomic Analysis and Interpretation Market
5.1 Overview
5.2 Legal Requirements and Framework in U.S.
5.3 Legal Requirements and Framework in Europe
5.4 Legal Requirements and Framework in Asia-Pacific
5.4.1 China
5.4.2 Japan
6.1 Overview
6.2 Iceberg Analysis – Global Genomic Data Analysis and Interpretation Market
6.3 Impact Analysis
6.4 Market Drivers
6.4.1 Decreasing Cost of Sequencing
6.4.2 Global Increase in Cancer Prevalence
6.4.3 Increasing Number of Population Genomics Initiatives
6.5 Market Restraints
6.5.1 Lack of High Complexity Genomic Testing Centers in High Potential Markets
6.5.2 Challenges Pertaining to Genomic Data Storage
6.5.3 Scarcity of Knowledge Dissemination Pertaining to Advanced Diagnostic Capabilities
6.6 Market Opportunities
6.6.1 Massive Scope for Adoption of Genomic Data Analysis Software in Emerging Nations
6.6.2 Novel Diagnostic Applications
7.1 Product Launch and Upgrades
7.2 Synergistic Activities
7.3 Acquisitions
7.4 Market Share Analysis, by Company, 2018-2019
7.5 Growth Share Analysis
7.5.1 Growth Share Analysis (by Company)
7.5.2 Growth Share Analysis (by Application)
8.1 Overview
8.2 Software
8.3 Services
8.3.1 Licenses
8.3.2 Maintenance
9.1 Overview
9.2 Next-Generation Sequencing (NGS)
9.3 Polymerase Chain Reaction (PCR)
9.4 Microarray
9.5 Other Genomic Platforms
10.1 Overview
10.2 Research Applications
10.2.1 Omics-Data Analysis
10.2.1.1 Transcriptomics
10.2.1.2 Microbiomics
10.2.1.3 Proteomics
10.2.1.4 Other Omics-Data Analysis
10.2.2 Population Genomics
10.2.3 Annotation and Gene Expression
10.2.4 Other Research Applications
10.3 Clinical Applications
10.3.1 Oncology
10.3.2 Rare Diseases
10.3.3 Infectious Diseases
10.3.4 Sexual and Reproductive Health
10.3.5 Other Clinical Applications
11.1 Overview
11.2 Research and Academic Institutions
11.3 Biotechnology and Biopharmaceutical Companies
11.4 Hospitals and Diagnostic Laboratories
11.5 Contract Research Organizations
11.6 Forensic Laboratories
11.7 Other End Users
12.1 Overview
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.2.3 North America Genomic Data Analysis and Interpretation Market (by Application), 2019-2030
12.3 Europe
12.3.1 Germany
12.3.2 U.K.
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 Netherlands
12.3.7 Rest-of-Europe
12.3.8 Europe Genomic Data Analysis and Interpretation Market (by Application), 2019-2030
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 Australia
12.4.5 South Korea
12.4.6 Rest-of-Asia-Pacific
12.4.7 Asia-Pacific Genomic Data Analysis and Interpretation Market (by Application), 2019-2030
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest-of-Latin-America
12.5.4 Latin America Genomic Data Analysis and Interpretation Market (by Application), 2019-2030
12.6 Rest-of-the-World
13.1 Overview
13.2 10x Genomics, Inc.
13.2.1 Company Overview
13.2.2 Role of 10x Genomics, Inc. in the Global Genomic Data Analysis and Interpretation Market
13.2.3 Financials
13.2.4 Key Insights About Financial Health of the Company
13.2.5 SWOT Analysis
13.3 Agilent Technologies, Inc.
13.3.1 Company Overview
13.3.2 Role of Agilent Technologies, Inc. in the Global Genomic Data Analysis and Interpretation Market
13.3.3 Financials
13.3.4 Key Insights About Financial Health of the Company
13.3.5 SWOT Analysis
13.4 ASURAGEN, INC.
13.4.1 Company Overview
13.4.2 Role of ASURAGEN, INC. in the Global Genomic Data Analysis and Interpretation Market
13.4.3 SWOT Analysis
13.5 Beijing Genomics Institute (BGI) Genomics Co., Ltd
13.5.1 Company Overview
13.5.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global Genomic Data Analysis and Interpretation Market
13.5.3 SWOT Analysis
13.6 Bio-Rad Laboratories, Inc.
13.6.1 Company Overview
13.6.2 Role of Bio-Rad Laboratories, Inc. in the Global Genomic Data Analysis and Interpretation Market
13.6.3 Financials
13.6.4 Key Insights About Financial Health of the Company
13.6.5 SWOT Analysis
13.7 DNASTAR
13.7.1 Company Overview
13.7.2 Roles of DNASTAR in the Global Genomic Data Analysis and Interpretation Market
13.7.3 SWOT Analysis
13.8 F. Hoffmann-La Roche Ltd
13.8.1 Company Overview
13.8.2 Role of F. Hoffmann-La Roche Ltd. in the Global Genomic Data Analysis and Interpretation Market
13.8.3 Financials
13.8.4 Key Insights About Financial Health of the Company
13.8.5 SWOT Analysis
13.9 Golden Helix, Inc.
13.9.1 Company Overview
13.9.2 Role of Golden Helix, Inc. in the Global Genomic Data Analysis and Interpretation Market
13.9.3 SWOT Analysis
13.10 Illumina, Inc.
13.10.1 Company Overview
13.10.2 Role of Illumina, Inc. in the Global Genomic Data Analysis and Interpretation Market
13.10.3 Financials
13.10.4 Key Insights About Financial Health of the Company
13.10.5 SWOT Analysis
13.11 Oxford Nanopore Technologies, Inc.
13.11.1 Company Overview
13.11.2 Role of Oxford Nanopore Technologies, Inc. in the Global Genomic Data Analysis and Interpretation Market
13.11.3 SWOT Analysis
13.12 Pacific Biosciences of California, Inc.
13.12.1 Company Overview
13.12.2 Role of Pacific Biosciences of California, Inc. in the Global Genomic Data Analysis and Interpretation Market
13.12.3 Financials
13.12.4 Key Insights About Financial Health of the Company
13.12.5 SWOT Analysis
13.13 Partek Inc.
13.13.1 Company Overview
13.13.2 Role of Partek Inc. in the Global Genomic Data Analysis and Interpretation Market
13.13.3 SWOT Analysis
13.14 QIAGEN N.V
13.14.1 Company Overview
13.14.2 Role of QIAGEN N.V. in the Global Genomic Data Analysis and Interpretation Market
13.14.3 Financials
13.14.4 Key Insights About Financial Health of the Company
13.14.5 SWOT Analysis
13.15 SoftGenetics, LLC.
13.15.1 Company Overview
13.15.2 Role of SoftGenetics, LLC in the Global Genomic Data Analysis and Interpretation Market
13.15.3 SWOT Analysis
13.16 Thermo Fisher Scientific Inc.
13.16.1 Company Overview
13.16.2 Role of Thermo Fisher Scientific Inc. in the Global Genomic Data Analysis and Interpretation Market
13.16.3 Financials
13.16.4 Key Insights About Financial Health of the Company
13.16.5 SWOT Analysis
Table 6.1: Likert Scale
Table 6.2: Impact Analysis of Market Drivers
Table 6.3: Impact Analysis of Market Restraints
Table 8.1: Examples of Software in the Global Genomic Data Analysis and Interpretation Market
Figure 1: Annual NIH Funding in Human Genomics Research, FY2013-FY2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Genomic Data Analysis and Interpretation Market
Figure 3: Global Genomic Data Analysis and Interpretation Market (by Product), $Million, 2019 vs. 2030
Figure 4: Global Genomic Data Analysis and Interpretation Market (by Genomic Platform), $Million, 2019 vs. 2030
Figure 5: Global Genomic Data Analysis and Interpretation Market (by Application), $Million, 2019 vs. 2030
Figure 6: Global Genomic Data Analysis and Interpretation Market (by End User), $Million, 2019 vs. 2030
Figure 7: Global Genomic Data Analysis and Interpretation Market Snapshot
Figure 2.1: Global Genomics Data Analysis and Interpretation, Market Segmentation
Figure 2.2: Global Genomic Data Analysis and Interpretation Market: Methodology
Figure 3.1: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.2: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 4.2: Global Genomic Data Analysis and Interpretation Market: COVID-19 Impact
Figure 6.1: Iceberg Analysis – Global Genomic Data Analysis and Interpretation Market
Figure 6.2: Decreasing Cost and Increasing Output (TB) of Genome Sequencing, 2009-2025
Figure 6.3: Global Cancer Burden, 2018
Figure 7.1: Share of Key Developments and Strategies, January 2017-November 2020
Figure 7.2: Share of Product Launch and Upgrades (by Company), January 2017–November 2020
Figure 7.3: Share of Synergistic Activities (by Company), January 2017- November 2020
Figure 7.4: Share of Acquisitions (by Company), January 2017-November 2020
Figure 7.5: Market Share Analysis for Global Genomic Data Analysis and Interpretation Market, 2018 and 2019
Figure 7.6: Growth Share Analysis for Global Genomic Data Analysis and Interpretation Market (by Company), 2019
Figure 7.7: Growth Share Analysis for Global Genomic Data Analysis and Interpretation Market (by Application), 2018-2019
Figure 8.1: Global Genomic Data Analysis and Interpretation Market (by Product Type)
Figure 8.2: Global Genomic Data Analysis and Interpretation Market (by Product Type), 2019 and 2030
Figure 8.3: Global Genomic Data Analysis and Interpretation Market (Software), $Million, 2019-2030
Figure 8.4: Global Genomic Data Analysis and Interpretation Market (by Services), 2019 and 2030
Figure 8.5: Global Genomic Data Analysis and Interpretation Market (by Services), $Million, 2019-2030
Figure 8.6: Global Genomic Data Analysis and Interpretation Market (Licenses), $Million, 2019-2030
Figure 8.7: Global Genomic Data Analysis and Interpretation Market (Maintenance), $Million, 2019-2030
Figure 9.1: Global Genomic Data Analysis and Interpretation Market (by Genomic Platform)
Figure 9.2: Global Genomic Data Analysis and Interpretation Market (by Genomic Platform), 2019 and 2030
Figure 9.3: Primary Data Analysis in NGS
Figure 9.4: Secondary Data Analysis in NGS
Figure 9.5: Tertiary Data Analysis in NGS
Figure 9.6: Global Genomic Data Analysis and Interpretation Market (NGS), $Million, 2019-2030
Figure 9.7: Global Genomic Data Analysis and Interpretation Market (PCR), $Million, 2019-2030
Figure 9.8: Global Genomic Data Analysis and Interpretation Market (Microarray), $Million, 2019-2030
Figure 9.9: Global Genomic Data Analysis and Interpretation Market (Other Genomic Platforms), $Million, 2019-2030
Figure 10.1: Global Genomic Data Analysis and Interpretation Market (by Application)
Figure 10.2: Global Genomic Data Analysis and Interpretation Market (by Application), $Million, 2019-2030
Figure 10.3: Global Genomic Data Analysis and Interpretation Market (by Research Applications), $Million, 2019-2030
Figure 10.4: Global Genomic Data Analysis and Interpretation Market (by Omics-Data Analysis), $Million, 2019-2030
Figure 10.5: Global Genomic Data Analysis and Interpretation Market (Transcriptomics), $Million, 2019-2030
Figure 10.6: Global Genomic Data Analysis and Interpretation Market (Microbiomics), $Million, 2019-2030
Figure 10.7: Global Genomic Data Analysis and Interpretation Market (Proteomics), $Million, 2019-2030
Figure 10.8: Global Genomic Data Analysis and Interpretation Market (Other Omics-Data Analysis), $Million, 2019-2030
Figure 10.9: Global Genomic Data Analysis and Interpretation Market (Population Genomics), $Million, 2019-2030
Figure 10.10: Global Genomic Data Analysis and Interpretation Market (Annotation and Gene Expression), $Million, 2019-2030
Figure 10.11: Global Genomic Data Analysis and Interpretation Market (Other Research Applications), $Million, 2019-2030
Figure 10.12: Global Genomic Data Analysis and Interpretation Market (by Clinical Application), 2019 and 2030
Figure 10.13: Global Genomic Data Analysis and Interpretation Market (Oncology), $Million, 2019-2030
Figure 10.14: Global Genomic Data Analysis and Interpretation Market (Rare Diseases), $Million, 2019-2030
Figure 10.15: Global Genomic Data Analysis and Interpretation Market (Infectious Diseases), $Million, 2019-2030
Figure 10.16: Global Genomic Data Analysis and Interpretation Market (Sexual and Reproductive Health), $Million, 2019-2030
Figure 10.17: Global Genomic Data Analysis and Interpretation Market (Other Clinical Applications), $Million, 2019-2030
Figure 11.1: Global Genomic Data Analysis and Interpretation Market (by End User), $Million, 2019-2030
Figure 11.2: Global Genomic Data Analysis and Interpretation Market (Research and Academic Institutions), $Million, 2019-2030
Figure 11.3: Global Genomic Data Analysis and Interpretation Market (Biotechnology and Pharmaceutical Companies), $Million, 2019-2030
Figure 11.4: Global Genomic Data Analysis and Interpretation Market (Hospitals and Diagnostic Laboratories), $Million, 2019-2030
Figure 11.5: Global Genomic Data Analysis and Interpretation Market (Contract Research Organizations), $Million, 2019-2030
Figure 11.6: Global Genomic Data Analysis and Interpretation Market (Forensic Laboratories), $Million, 2019-2030
Figure 11.7: Global Genomic Data Analysis and Interpretation Market (Other End Users), $Million, 2019-2030
Figure 12.1: Global Genomic Data Analysis and Interpretation Market (by Region), $Million, 2019-2030
Figure 12.2: Global Genomic Data Analysis and Interpretation Market (by Region), 2019-2030
Figure 12.3: North America Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.4: North America: Market Dynamics
Figure 12.5: North America Genomic Data Analysis and Interpretation Market (by Country), $Million, 2019-2030
Figure 12.6: U.S. Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.7: Canada Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.8: North America Genomic Data Analysis and Interpretation Market (by Application), 2019-2030
Figure 12.9: Europe Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.10: Europe: Market Dynamics
Figure 12.11: Europe Genomic Data Analysis and Interpretation Market (by Country), $Million, 2019-2030
Figure 12.12: Germany Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.13: U.K. Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.14: France Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.15: Italy Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.16: Spain Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.17: Netherlands Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.18: Rest-of-Europe Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.19: Europe Genomic Data Analysis and Interpretation Market (by Application), 2019-2030
Figure 12.20: Asia-Pacific Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.21: APAC: Market Dynamics
Figure 12.22: APAC Genomic Data Analysis and Interpretation Market (by Country), $Million, 2019-2030
Figure 12.23: China Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.24: Japan Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.25: India Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.26: Australia Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.27: South Korea Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.28: Rest-of-Asia-Pacific Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.29: Asia-Pacific Genomic Data Analysis and Interpretation Market (by Application), 2019-2030
Figure 12.30: Latin America Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.31: Latin America: Market Dynamics
Figure 12.32: Latin America Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.33: Brazil Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.34: Mexico Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.35: Rest-of-Latin America Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 12.36: Latin America Genomic Data Analysis and Interpretation Market (by Application), 2019-2030
Figure 12.37: RoW Genomic Data Analysis and Interpretation Market, $Million, 2019-2030
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: 10x Genomics, Inc.: Overall Product Portfolio
Figure 13.3: 10x Genomics, Inc.: Overall Financials, 2017-2019
Figure 13.4: 10x Genomics, Inc.: Revenue (by Segment), 2017-2019
Figure 13.5: 10x Genomics, Inc.: Revenue (by Region), 2017-2019
Figure 13.6: 10x Genomics, Inc. R&D Expenditure, 2017-2019
Figure 13.7: 10x Genomics, Inc.: SWOT Analysis
Figure 13.8: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 13.9: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 13.10: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 13.11: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 13.12: Agilent Technologies, Inc. R&D Expenditure, 2017-2019
Figure 13.13: Agilent Technologies, Inc.: SWOT Analysis
Figure 13.14: ASURAGEN, INC.: Overall Product Portfolio
Figure 13.15: ASURAGEN, INC.: SWOT Analysis
Figure 13.16: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Overall Product Portfolio
Figure 13.17: Beijing Genomics Institute (BGI) Genomics Co., Ltd.: SWOT Analysis
Figure 13.18: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 13.19: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 13.20: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 13.21: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 13.22: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 13.23: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 13.24: DNASTAR: Overall Product Portfolio
Figure 13.25: DNASTAR: SWOT Analysis
Figure 13.26: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
Figure 13.27: F. Hoffmann-La Roche Ltd.: Overall Financials, 2017-2019
Figure 13.28: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), 2017-2019
Figure 13.29: F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics), 2017-2019
Figure 13.30: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2017-2019
Figure 13.31: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2017-2019
Figure 13.32: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 13.33: Golden Helix, Inc.: Product Portfolio
Figure 13.34: Golden Helix, Inc.: SWOT Analysis
Figure 13.35: Illumina, Inc.: Overall Product Portfolio
Figure 13.36: Illumina, Inc.: Overall Financials, 2017-2019
Figure 13.37: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 13.38: Illumina, Inc.: Revenue (by Region), 2017-2020
Figure 13.39: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 13.40: Illumina, Inc.: SWOT Analysis
Figure 13.41: Oxford Nanopore Technologies, Inc.: Product Portfolio
Figure 13.42: Oxford Nanopore Technologies, Inc.: SWOT Analysis
Figure 13.43: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 13.44: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
Figure 13.45: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
Figure 13.46: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
Figure 13.47: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
Figure 13.48: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 13.49: Partek Inc.: Product Portfolio
Figure 13.50: Partek Inc.: SWOT Analysis
Figure 13.51: QIAGEN N.V.: Product Portfolio
Figure 13.52: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 13.53: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 13.54: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 13.55: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 13.56: QIAGEN N.V.: SWOT Analysis
Figure 13.57: SoftGenetics, LLC: Product Portfolio
Figure 13.58: SoftGenetics, LLC: SWOT Analysis
Figure 13.59: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 13.60: Thermo Fisher Scientific Inc.: Overall Financials: 2017-2020
Figure 13.61: Thermo Fisher Scientific Inc.: Sales (by Segment): 2017-2020
Figure 13.62: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 13.63: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 13.64: Thermo Fisher Scientific Inc.: SWOT Analysis
Report Description
Market Report Coverage - Genomic Data Analysis and Interpretation |
|||
Base Year |
2019 |
Market Size in 2019 |
$738.7 Million |
Forecast Period |
2020-2030 |
Value Projection and Estimation by 2030 |
$2.10 Billion |
CAGR During Forecast Period |
10.21% |
Number of Tables |
4 |
Number of Pages |
241 |
Number of Figures |
164 |
Research Hours |
700 |
|
|
Market Segmentation |
• Product – Software and Services (License and Maintenance) • Genomic Platform – Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, and Other Genomic Platforms • Applications – Research (Omics-Data Analysis, Population Sequencing, Annotation and Gene Expression, and Other Research Applications) and Clinical (Oncology, Rare Diseases, Infectious diseases, Sexual and Reproductive Health, and Other Clinical Applications) • End User – Research and Academic Institutions, Biotechnology and Biopharmaceutical Companies, Hospitals and Diagnostic Laboratories, Contract Research Organizations, Forensic Laboratories, and Other End Users |
||
Regional Segmentation |
• North America – U.S. and Canada • Europe – Germany, U.K., France, Italy, Spain, the Netherlands, and Rest-of-Europe • Asia-Pacific – China, Japan, India, Australia, South Korea, and Rest-of-Asia-Pacific • Latin America – Brazil, Mexico, and Rest-of-Latin America • Rest-of-the-World |
||
Growth Drivers |
• Decreasing Cost of Sequencing • Global Increase in Cancer Prevalence • Increasing Number of Population Genomics Initiative |
||
Market Challenges |
• Lack of High Complexity Genomic Testing Centers in High Potential Markets • Challenges Pertaining to Genomic Data Storage • Scarcity of Knowledge Dissemination Pertaining to Advanced Diagnostic Capabilities |
||
Market Opportunities |
• Massive Scope for the Adoption of Genomic Data Analysis Software in the Emerging Nations • Novel Diagnostic Applications |
||
Key Companies Profiled |
10x Genomics, Inc., Agilent Technologies, Inc., ASURAGEN INC., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Bio-Rad Laboratories, Inc., DNASTAR, F. Hoffmann-La Roche Ltd., Golden Helix, Inc., Illumina, Inc., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., Partek Inc., QIAGEN N.V., SoftGenetics LLC, and Thermo Fisher Scientific Inc. |
Key Questions Answered in this Report:
• How is genomic data analysis and interpretation revolutionizing the field of research and diagnostics?
• What are the major market drivers, challenges, and opportunities in the global genomic data analysis and interpretation market?
• What are the underlying structures resulting in the emerging trends within the global genomic data analysis and interpretation market?
• How the COVID-19 pandemic impacted the genomic data analysis and interpretation landscape?
• What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to genomics?
• What are the potential entry barriers expected to be faced by the companies willing to enter in a particular region?
• How is each segment of the market expected to grow during the forecast period from 2020 to 2030, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Product Type (Software and Services)
o Genomic Platform (NGS, PCR, Microarray, and Others)
o Application (Research and Clinical)
o End User (Research and Academic Institutions, Biotechnology and Pharmaceutical Companies, Corporate Research Organizations, Hospitals and Diagnostic Laboratories, Forensic Laboratories, and Others)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the companies in the region of their operation?
• Who are the leading players with significant offerings to the global genomic data analysis and interpretation market? What is the expected market dominance for each of these leading players?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the current unmet needs that are being faced?
Market Overview
Healthcare experts at BIS have found genomic data analysis and interpretation industry to be one of the most rapidly evolving and dynamic markets and the global market for Genomic data analysis and interpretation is predicted to grow at a CAGR of 10.21% over the forecast period of 2020-2030. The market is driven by certain factors, which include decreasing cost of sequencing, global increase in cancer prevalence, and increasing number of population genomics initiative, among others, are fueling the growth of the global genomic data analysis and interpretation market.
The market is favored by the developments in the field of genomics and bioinformatics. Currently, the genomic data analysis and interpretation industry is witnessing an upsurge due to the growing number of genomic research initiatives being undertaken by the developing and developed countries coupled with the decreasing cost of sequencing, resulting in the high demand for software solutions for genomic data analysis. Additionally, high adoption of sequencing instruments by the researchers and clinicians, coupled with the growing prevalence of complex diseases, such as cancer, are some of the critical factors expected to bolster the market growth.
Furthermore, biotechnology companies are focusing on the development of robust genomic data analysis software solutions for a wide range of clinical applications to support clinicians in conducting an in-depth analysis.
Within the research report, the market is segmented on the basis of product, genomic platform, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the number of cases associated with cancer has created a buzz among the biotechnology companies to further invest in the development of reliable genomic software solutions for data analysis, further aiding clinicians to offer precision oncology treatments. Due to the presence of a diverse product portfolio and intense market penetration, Thermo Fisher Scientific Inc. has been a pioneer in this field and has been a significant competitor in this market.
On the basis of region, North America holds the largest share of the genomic data analysis and interpretation market due to high infusion of funding from the government organizations for conducting research on genomics and bioinformatics, rising prevalence of cancer, growing awareness about precision medicine, and decreasing cost of sequencing, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2020-2030.
Global Genomic Data Analysis and Interpretation Market
Focus on Products, Genomic Platforms, Applications, End Users, Country Data (15 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
Frequently Asked Questions
The genomic data analysis and interpretation market is projected to reach $2.10 Billion by 2030 from $738.7 Million in 2019.
Decreasing cost of sequencing, global increase in cancer prevalence, and increasing number of population genomics initiative are some of the factors driving the growth of the market.
The genomic data analysis and interpretation can be used for various purposes including research (omics-data analysis, population sequencing, annotation and gene expression, and other research applications) and clinical (oncology, rare diseases, infectious diseases, sexual and reproductive health, and other clinical applications).
Factors that are responsible for restraining the growth of the market, include lack of high complexity genomic testing centers in high potential markets, challenges pertaining to genomic data storage, and scarcity of knowledge dissemination pertaining to advanced diagnostic capabilities.
Some of the major key players operating in the market include 10x Genomics, Inc., Agilent Technologies, Inc., ASURAGEN INC., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Bio-Rad Laboratories, Inc., DNASTAR, F. Hoffmann-La Roche Ltd., Golden Helix, Inc., Illumina, Inc., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., Partek Inc., QIAGEN N.V., SoftGenetics LLC, and Thermo Fisher Scientific Inc.